Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Clivatuzumab (Anti-MUC1)
For research use only. Not for use in humans.

Clivatuzumab (Anti-MUC1)

Synonyms: CD227,MUC-1

Clivatuzumab (Anti-MUC1) is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. MW: 145.5 kD.

Clivatuzumab (Anti-MUC1)

Click to purchase the isotype control of Clivatuzumab (Anti-MUC1)

Quality Control

Batch: A239701 Purity: 99% Protein concentration: 6.88mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Clivatuzumab (Anti-MUC1) is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. MW: 145.5 kD.

Product Details

CAS No. 1622075-09-5
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05812326 COMPLETED Drug: AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells Advanced Breast Cancer; Breast Neoplasm Malignant Female Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2019-05-17 PHASE1; PHASE2
NCT03706326 UNKNOWN Advanced Esophageal Cancer The First Affiliated Hospital of Guangdong Pharmaceutical University 2018-09-28 PHASE1; PHASE2
NCT03525782 UNKNOWN Drug: PD-1 mAb Lung Neoplasm Malignant; Non-small Cell Lung Cancer The First Affiliated Hospital of Guangdong Pharmaceutical University 2018-02-01 PHASE1; PHASE2
NCT02544880 COMPLETED Drug: Tadalafil Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer Donald T. Weed, MD, FACS 2016-04-25 PHASE1
NCT02617134 UNKNOWN Malignant Glioma of Brain; Colorectal Carcinoma; Gastric Carcinoma PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2015-11 PHASE1; PHASE2
NCT02587689 UNKNOWN Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Pancreatic Carcinoma; Triple-Negative Invasive Breast Carcinoma PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2015-10 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2023-04-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.